O	0	1	A
O	2	10	protocol
O	11	14	for
O	15	16	a
O	17	28	multicentre
O	28	29	,
O	30	38	parallel
O	38	39	-
O	39	44	group
O	44	45	,
O	46	55	pragmatic
O	56	66	randomised
O	67	77	controlled
O	78	83	trial
O	84	86	to
O	87	95	evaluate
O	96	99	the
O	100	109	NEVERMIND
O	110	116	system
O	117	119	in
O	120	130	preventing
O	131	134	and
O	135	143	treating
B-condition	144	154	depression
O	155	157	in
O	158	166	patients
O	167	171	with
O	172	178	severe
O	179	186	somatic
O	187	197	conditions
O	197	198	.

O	199	209	Depressive
O	210	218	symptoms
O	219	222	are
O	223	229	common
O	230	232	in
O	233	244	individuals
O	245	254	suffering
O	255	259	from
O	260	266	severe
O	267	274	somatic
O	275	285	conditions
O	285	286	.

O	287	292	There
O	293	295	is
O	296	297	a
O	298	302	lack
O	303	305	of
O	306	319	interventions
O	320	323	and
O	324	332	evidence
O	332	333	-
O	333	338	based
O	339	352	interventions
O	353	359	aiming
O	360	362	to
O	363	369	reduce
O	370	380	depressive
O	381	389	symptoms
O	390	392	in
O	393	401	patients
O	402	406	with
O	407	413	severe
O	414	421	somatic
O	422	432	conditions
O	432	433	.

O	434	437	The
O	438	441	aim
O	442	444	of
O	445	448	the
O	449	458	NEVERMIND
O	459	466	project
O	467	469	is
O	470	472	to
O	473	480	address
O	481	486	these
O	487	493	issues
O	494	497	and
O	498	505	provide
O	506	514	evidence
O	515	517	by
O	518	525	testing
O	526	529	the
O	530	539	NEVERMIND
O	540	546	system
O	546	547	,
O	548	556	designed
O	557	559	to
O	560	566	reduce
O	567	570	and
O	571	578	prevent
O	579	589	depressive
O	590	598	symptoms
O	599	601	in
O	602	612	comparison
O	613	615	to
O	616	625	treatment
O	626	628	as
O	629	634	usual
O	634	635	.

O	636	639	The
O	640	649	NEVERMIND
O	650	655	study
O	656	658	is
O	659	660	a
O	661	669	parallel
O	669	670	-
O	670	676	groups
O	676	677	,
O	678	687	pragmatic
O	688	698	randomised
O	699	709	controlled
O	710	715	trial
O	716	718	to
O	719	725	assess
O	726	729	the
O	730	743	effectiveness
O	744	746	of
O	747	750	the
O	751	760	NEVERMIND
O	761	767	system
O	768	770	in
O	771	779	reducing
O	780	790	depressive
O	791	799	symptoms
O	800	805	among
O	806	817	individuals
O	818	822	with
O	823	829	severe
O	830	837	somatic
O	838	848	conditions
O	848	849	.

O	850	853	The
O	854	863	NEVERMIND
O	864	870	system
O	871	880	comprises
O	881	882	a
O	883	888	smart
O	889	894	shirt
O	895	898	and
O	899	900	a
O	901	905	user
O	906	915	interface
O	915	916	,
O	917	919	in
O	920	923	the
O	924	928	form
O	929	931	of
O	932	933	a
O	934	940	mobile
O	941	952	application
O	952	953	.

O	954	957	The
O	958	964	system
O	965	967	is
O	968	969	a
B-intervention	970	974	real
I-intervention	974	975	-
I-intervention	975	979	time
I-intervention	980	988	decision
I-intervention	989	996	support
I-intervention	997	1003	system
O	1003	1004	,
O	1005	1011	aiming
O	1012	1014	to
O	1015	1022	predict
O	1023	1026	the
O	1027	1035	severity
O	1036	1039	and
O	1040	1045	onset
O	1046	1048	of
O	1049	1059	depressive
O	1060	1068	symptoms
O	1069	1071	by
O	1072	1081	modelling
O	1082	1085	the
O	1086	1090	well
O	1090	1091	-
O	1091	1096	being
O	1097	1106	condition
O	1107	1109	of
O	1110	1118	patients
O	1119	1124	based
O	1125	1127	on
O	1128	1141	physiological
O	1142	1146	data
O	1146	1147	,
O	1148	1152	body
O	1153	1161	movement
O	1161	1162	,
O	1163	1166	and
O	1167	1170	the
O	1171	1181	recurrence
O	1182	1184	of
O	1185	1191	social
O	1192	1204	interactions
O	1204	1205	.

O	1206	1209	The
O	1210	1215	study
O	1216	1224	includes
B-total-participants	1225	1228	330
B-eligibility	1229	1237	patients
I-eligibility	1238	1241	who
I-eligibility	1242	1246	have
I-eligibility	1247	1248	a
I-eligibility	1249	1258	diagnosis
I-eligibility	1259	1261	of
I-eligibility	1262	1272	myocardial
I-eligibility	1273	1283	infarction
I-eligibility	1283	1284	,
I-eligibility	1285	1291	breast
I-eligibility	1292	1298	cancer
I-eligibility	1298	1299	,
I-eligibility	1300	1308	prostate
I-eligibility	1309	1315	cancer
I-eligibility	1315	1316	,
I-eligibility	1317	1323	kidney
I-eligibility	1324	1331	failure
I-eligibility	1331	1332	,
I-eligibility	1333	1335	or
I-eligibility	1336	1341	lower
I-eligibility	1342	1346	limb
I-eligibility	1347	1357	amputation
O	1357	1358	.

O	1359	1371	Participants
O	1372	1375	are
O	1376	1386	randomised
O	1387	1389	in
O	1390	1396	blocks
O	1397	1399	of
O	1400	1403	ten
O	1404	1406	to
O	1407	1413	either
O	1414	1417	the
O	1418	1427	NEVERMIND
O	1428	1440	intervention
O	1441	1443	or
B-control	1444	1453	treatment
I-control	1454	1456	as
I-control	1457	1462	usual
I-control	1463	1465	as
I-control	1466	1469	the
I-control	1470	1477	control
I-control	1478	1483	group
O	1483	1484	.

O	1485	1493	Clinical
O	1494	1504	interviews
O	1505	1508	and
O	1509	1519	structured
O	1520	1534	questionnaires
O	1535	1538	are
O	1539	1551	administered
O	1552	1554	at
O	1555	1563	baseline
O	1563	1564	,
O	1565	1567	at
O	1568	1570	12
O	1571	1576	weeks
O	1576	1577	,
O	1578	1581	and
O	1582	1584	24
O	1585	1590	weeks
O	1591	1593	to
O	1594	1600	assess
O	1601	1608	whether
O	1609	1612	the
O	1613	1622	NEVERMIND
O	1623	1629	system
O	1630	1632	is
O	1633	1641	superior
O	1642	1644	to
O	1645	1654	treatment
O	1655	1657	as
O	1658	1663	usual
O	1663	1664	.

O	1665	1668	The
O	1669	1677	endpoint
O	1678	1680	of
O	1681	1688	primary
O	1689	1697	interest
O	1698	1700	is
B-outcome-Measure	1701	1705	Beck
I-outcome-Measure	1706	1716	Depression
I-outcome-Measure	1717	1726	Inventory
I-outcome-Measure	1727	1729	II
I-outcome-Measure	1730	1731	(
I-outcome-Measure	1731	1734	BDI
I-outcome-Measure	1734	1735	-
I-outcome-Measure	1735	1737	II
I-outcome-Measure	1737	1738	)
I-outcome-Measure	1739	1741	at
I-outcome-Measure	1742	1744	12
I-outcome-Measure	1745	1750	weeks
O	1751	1758	defined
O	1759	1761	as
O	1762	1763	(
O	1763	1764	i
O	1764	1765	)
O	1766	1769	the
O	1770	1778	severity
O	1779	1781	of
O	1782	1792	depressive
O	1793	1801	symptoms
O	1802	1804	as
O	1805	1813	measured
O	1814	1816	by
O	1817	1820	the
O	1821	1824	BDI
O	1824	1825	-
O	1825	1827	II
O	1827	1828	.

O	1829	1838	Secondary
O	1839	1847	outcomes
O	1848	1855	include
B-outcome-Measure	1856	1866	prevention
I-outcome-Measure	1867	1869	of
I-outcome-Measure	1870	1873	the
I-outcome-Measure	1874	1879	onset
I-outcome-Measure	1880	1882	of
I-outcome-Measure	1883	1893	depressive
I-outcome-Measure	1894	1902	symptoms
O	1902	1903	,
B-outcome	1904	1911	changes
I-outcome	1912	1914	in
I-outcome	1915	1922	quality
I-outcome	1923	1925	of
I-outcome	1926	1930	life
O	1930	1931	,
B-outcome-Measure	1932	1941	perceived
I-outcome-Measure	1942	1948	stigma
O	1948	1949	,
O	1950	1953	and
B-outcome-Measure	1954	1958	self
I-outcome-Measure	1958	1959	-
I-outcome-Measure	1959	1967	efficacy
O	1967	1968	.

O	1969	1974	There
O	1975	1977	is
O	1978	1979	a
O	1980	1984	lack
O	1985	1987	of
O	1988	1996	evidence
O	1996	1997	-
O	1997	2002	based
O	2003	2016	interventions
O	2017	2023	aiming
O	2024	2026	to
O	2027	2033	reduce
O	2034	2037	and
O	2038	2045	prevent
B-outcome	2046	2056	depressive
I-outcome	2057	2065	symptoms
O	2066	2068	in
O	2069	2077	patients
O	2078	2082	with
O	2083	2089	severe
O	2090	2097	somatic
O	2098	2108	conditions
O	2108	2109	.

O	2110	2112	If
O	2113	2116	the
O	2117	2126	NEVERMIND
O	2127	2133	system
O	2134	2136	is
O	2137	2146	effective
O	2146	2147	,
O	2148	2150	it
O	2151	2155	will
O	2156	2163	provide
O	2164	2174	healthcare
O	2175	2182	systems
O	2183	2187	with
O	2188	2189	a
O	2190	2195	novel
O	2196	2199	and
O	2200	2210	innovative
O	2211	2217	method
O	2218	2220	to
O	2221	2227	attend
O	2228	2230	to
O	2231	2241	depressive
O	2242	2250	symptoms
O	2251	2253	in
O	2254	2262	patients
O	2263	2267	with
O	2268	2274	severe
O	2275	2282	somatic
O	2283	2293	conditions
O	2293	2294	.

O	2295	2307	DRKS00013391
O	2307	2308	.

O	2309	2319	Registered
O	2320	2322	23
O	2323	2331	November
O	2332	2336	2017
O	2336	2337	.
